Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.20 USD
+0.01 (0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.19 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Earnings News For ACRS
-
Aclaris: Q4 Earnings Snapshot
-
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
-
Aclaris: Q3 Earnings Snapshot
-
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
-
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
-
Aclaris: Q1 Earnings Snapshot
-
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
-
Aclaris: Q4 Earnings Snapshot
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
-
Aclaris: Q3 Earnings Snapshot
-
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
-
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
-
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates
-
Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to Decline
-
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
-
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
-
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release